Tag Archives: Joshua Schimmer

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Mylan (NASDAQ: MYL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) and Mylan (MYL – Research Report) with bullish sentiments. Ultragenyx Pharmaceutical (RARE) In a report released

Incyte (INCY) Gets a Buy Rating from Evercore ISI

In a report issued on February 14, Joshua Schimmer from Evercore ISI maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $92.00. The company’s shares closed last Monday at $78.45. According to TipRanks.com, Schimmer

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Amgen (AMGN – Research Report). Vertex Pharmaceuticals (VRTX) In a report issued on January 31, Joshua Schimmer from

Evercore ISI Remains a Buy on Incyte (INCY)

In a report issued on January 24, Joshua Schimmer from Evercore ISI maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $92.00. The company’s shares closed last Monday at $76.74. According to TipRanks.com, Schimmer

Prothena (PRTA) Receives a Buy from Evercore ISI

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Prothena (PRTA – Research Report) on December 20 and set a price target of $14.00. The company’s shares closed last Monday at $15.85, close to its 52-week high of $16.76.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Adamas Pharmaceuticals (NASDAQ: ADMS) and Eli Lilly & Co (NYSE: LLY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adamas Pharmaceuticals (ADMS – Research Report) and Eli Lilly & Co (LLY – Research Report). Adamas Pharmaceuticals (ADMS) In a report released today,